MCP-1 and MIP3-alpha serum levels in acute liver failure and molecular adsorbent recirculating system (MARS) treatment: A pilot study

References

• Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179–97
   PubMed Web of Science ®Google Scholar
• Rinella ME, Sanyal A. Intensive management of hepatic failure. Semin Respir Crit Care Med 2006; 27: 241–61
   PubMedGoogle Scholar
• Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 1034–9
   PubMedGoogle Scholar
• Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9: 290–7
   PubMed Web of Science ®Google Scholar
• Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109–19
   PubMed Web of Science ®Google Scholar
• Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468–75
   PubMed Web of Science ®Google Scholar
• Steiner C, Sen S, Stange J, Williams R, Jalan R. Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management. Liver Transpl 2004; 10: 1531–8
   PubMed Web of Science ®Google Scholar
• Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949–58
   PubMed Web of Science ®Google Scholar
• Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277–86
   PubMed Web of Science ®Google Scholar
• Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, et al. Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol 2003; 199: 335–44
   PubMedGoogle Scholar
• Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999; 154: 1711–20
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Chemokines. Blood 1997; 90: 909–28
   PubMed Web of Science ®Google Scholar
• Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409–26
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. J Viral Hepat 2002; 9: 213–20
   PubMedGoogle Scholar
• Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002; 17: 435–41
   PubMed Web of Science ®Google Scholar
• Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 103–10
   PubMed Web of Science ®Google Scholar
• Faybik P, Bacher A, Kozek-Langenecker SA, Steltzer H, Krenn CG, Unger S, et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006; 10: R24
   Google Scholar
• Miyake Y, Iwasaki Y, Terada R, Takaguchi K, Sakaguchi K, Shiratori Y. Systemic inflammatory response syndrome strongly affects the prognosis of patients with fulminant hepatitis B. J Gastroenterol 2007; 42: 485–92
   PubMedGoogle Scholar
• Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734–9
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247–54
   PubMed Web of Science ®Google Scholar
• Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci (Lond) 2003; 104: 47–63
   PubMedGoogle Scholar
• Yamaguchi Y, Matsumura F, Liang J, Okabe K, Ohshiro H, Ishihara K, et al. Neutrophil elastase and oxygen radicals enhance monocyte chemoattractant protein-1 expression after ischemia/reperfusion in rat liver. Transplantation 1999; 68: 1459–68
   PubMedGoogle Scholar
• Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 1999; 163: 6148–54
   PubMed Web of Science ®Google Scholar
• Marra F, DeFranco R, Grappone C, Parola M, Milani S, Leonarduzzi G, et al. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Invest Med 1999; 47: 66–75
   PubMedGoogle Scholar
• Yamaguchi M, Gabazza EC, Taguchi O, Yano Y, Ikoma J, Kaito M, et al. Decreased protein C activation in patients with fulminant hepatic failure. Scand J Gastroenterol 2006; 41: 331–7
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K, et al. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 2001; 34: 311–9
   PubMedGoogle Scholar
• Ankersmit HJ, Deicher R, Moser B, Teufel I, Roth G, Gerlitz S, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001; 125: 142–8
   PubMedGoogle Scholar
• Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999; 354: 550–5
   PubMedGoogle Scholar
• Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H. In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 1995; 10: 2244–9
   PubMed Web of Science ®Google Scholar
• Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, Duran C, et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res 2006; 37: 998–1003
   PubMed Web of Science ®Google Scholar
• Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996; 27: 640–6
   PubMed Web of Science ®Google Scholar